Authors: Alice Weatherston
Inhibikase Therapeutics Inc. have today announced the launch of an observational clinical study in patients with progressive multifocal leukoencephalopathy (PML), which is a possible side effect of a variety of drugs used in treatment for diseases such as multiple sclerosis, Crohn’s disease, ulcerative colitis and hematologic cancers as well as HIV/AIDS patients.
JC Virus (JCV) is the primary cause of PML and its transport from the kidney into the brain can be induced by a range of medications. Once in the brain JCV is capable of causing severe and irreversible damage which can lead to death. “The company has a robust method for measurement of viral load in living patients. We now wish to measure the relationship between JCV viral load and JCV antibody titer in patients who survived the acute phase of the infection,” explained Milton Werner, Inhibikase’s CEO.
“PML survivors are a treasure trove of information that can help us to better understand the natural history and clinical virology of the disease,” he continued. The company are now looking to expand their patient-base for the study.